يعرض 1 - 20 نتائج من 111 نتيجة بحث عن '"Ladwa, R."', وقت الاستعلام: 0.63s تنقيح النتائج
  1. 1
    Academic Journal
  2. 2
    Academic Journal

    Relation: Frontiers in Oncology; Ladwa, R; Chandra, J; Woo, WP; Finlayson, N; Liu, H; McGrath, M; See, A; Hughes, BG; Cooper, CL; Jackson, JE; Dzienis, M; Xu, Y; Panizza, B; Frazer, I; Porceddu, SV, A phase Ib study to assess the safety of the human papillomavirus DNA vaccine (AMV002) in combination with durvalumab for HPV-associated oropharyngeal squamous cell carcinoma, Frontiers in Oncology, 2024, 14, pp. 1419258; https://hdl.handle.net/10072/431751

  3. 3
    Academic Journal

    Relation: NHMRC/1175929; McLean, L. S., Lim, A. M., Bressel, M., Lee, J., Ladwa, R., Guminski, A. D., Hughes, B., Bowyer, S., Briscoe, K., Harris, S., Kukard, C., Zielinski, R., Alamgeer, M., Carlino, M., Mo, J., Park, J. J., Khattak, M. A., Day, F. & Rischin, D. (2024). Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study. MEDICAL JOURNAL OF AUSTRALIA, 220 (2), pp.80-90. https://doi.org/10.5694/mja2.52199.; http://hdl.handle.net/11343/344552

  4. 4
    Academic Journal
  5. 5
    Academic Journal
  6. 6
    Electronic Resource
  7. 7
    Academic Journal

    Relation: Weeramange, C. E., Shu, D., Tang, K. D., Batra, J., Ladwa, R., Kenny, L., Vasani, S., Frazer, I. H., Dolcetti, R., Ellis, J. J., Sturm, R. A., Leo, P. & Punyadeera, C. (2022). Analysis of human leukocyte antigen associations in human papillomavirus-positive and -negative head and neck cancer: Comparison with cervical cancer. CANCER, 128 (10), pp.1937-1947. https://doi.org/10.1002/cncr.34148.; http://hdl.handle.net/11343/301755

  8. 8
    Academic Journal
  9. 9
    Academic Journal
  10. 10
  11. 11
  12. 12
    Academic Journal
  13. 13
    Academic Journal
  14. 14
    Academic Journal
  15. 15
    Academic Journal
  16. 16
    Academic Journal

    Relation: pii: 10.1186/s12885-021-08644-4; Siu, H. W. D., Tebbutt, N., Chantrill, L., Karapetis, C., Steer, C., Wilson, K., Espinoza, D., Bailey, L., Yip, S., Cuff, J., Pavlakis, N., Thavaneswaran, S., Briscoe, K., Srivastav, R., Shannon, J., Segelov, E., Tie, J., Caird, S., Francesconi, A. ,. Burge, M. (2021). MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG). BMC CANCER, 21 (1), https://doi.org/10.1186/s12885-021-08644-4.; http://hdl.handle.net/11343/287789

  17. 17
    Academic Journal
  18. 18
    Academic Journal
  19. 19
    Academic Journal

    Relation: Cancer Immunology, Immunotherapy; Chandra, J; Woo, WP; Finlayson, N; Liu, HY; McGrath, M; Ladwa, R; Brauer, M; Xu, Y; Hanson, S; Panizza, B; Frazer, IH; Porceddu, SV, A phase 1, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a therapeutic human papillomavirus (HPV) DNA vaccine (AMV002) for HPV-associated head and neck cancer (HNC), Cancer Immunology, Immunotherapy, 2020; http://hdl.handle.net/10072/397510

  20. 20